Skip to main content
OpenTrials

Clinical trial condition

Purine-Pyrimidine Metabolism, Inborn Errors

Explore clinical trials studying Purine-Pyrimidine Metabolism, Inborn Errors. Study availability and eligibility vary by location and protocol.

266 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Purine-Pyrimidine Metabolism, Inborn Errors trial results

Completed

Allopurinol Outcome Study

NCT01391325

Conditions
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, +9 more
Locations
  • Birmingham, Alabama, United States
  • Birmingham, Alabama, United States
  • Bringham, Alabama, United States
  • Calera, Alabama, United States
View all 173 locations
View Trial Details
Completed

AMPED Outcomes Registry of Post-ED Pain Management

NCT01626235

Conditions
Agnosia, Arthritis, Arthritis, Gouty, +44 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • LSU Medical Center New Orleans, Louisiana, United States
  • University of Mississippi Medical Center Jackson, Mississippi, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

NCT01029652

Conditions
Acute Gout, Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Novartis Investigative Site Darlinghurst, New South Wales, Australia
  • Novartis Investigative Site Fitzroy, Victoria, Australia
  • Novartis Investigative Site Heidelberg, Victoria, Australia
  • Novartis Investigative Site Daw Park SA, Australia
View all 47 locations
View Trial Details
Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131

Conditions
Acute Gout, Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Pinnacle Research Group, LLC Anniston, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Novartis Investigative site Foley, Alabama, United States
  • Horizon Research Group, Inc. Mobile, Alabama, United States
View all 108 locations
View Trial Details
Completed

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602

Conditions
Acute Gouty Arthritis, Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +12 more
Locations
  • Novartis Investigative Site Anniston, Alabama, United States
  • Novartis Investigative Site Gulf Shores, Alabama, United States
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Chandler, Arizona, United States
View all 99 locations
View Trial Details
Completed

A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency

NCT01407874

Conditions
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, +20 more
Locations
  • Mobile, Alabama, United States
  • Peoria, Arizona, United States
  • Irvine, California, United States
  • Oldsmar, Florida, United States
View Trial Details

Related conditions